title: A US postmarketing evaluation of the frequency and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years: 2009-2010 season.
abstract: The 2007 US approval for use of Ann Arbor strain live attenuated influenza vaccine (LAIV) in children aged 24 through 59 months included precautions against use in (1) children <24 months and children aged 24 through 59 months with (2) asthma, (3) recurrent wheezing, and (4) altered immunocompetence. Results from the third season (2009-2010) of a 3-year study postmarketing commitment to monitor LAIV vaccination rates and frequency of hospitalizations or emergency department visits within 42 days after LAIV are reported here. As in the first 2 seasons, LAIV usage in cohorts 1, 2, and 4 were low relative to those in LAIV-recommended populations. The only numerically increased risk observed was for respiratory events in children aged <24 months administered LAIV, compared to those administered trivalent inactivated influenza vaccine (TIV). The number of children vaccinated with LAIV was small and precluded precise quantification of rare event.
authors: RTI Health Solutions, 3040 Cornwallis Road, Post Office Box 12194, Research Triangle Park, NC 27709, USA. ptennis@rti.org
authors: Patricia
authors: P
authors: Tennis
authors: Seth L
authors: SL
authors: Toback
authors: Elizabeth B
authors: EB
authors: Andrews
authors: Lisa J
authors: LJ
authors: McQuay
authors: Christopher S
authors: CS
authors: Ambrose
mesh_terms: D001249:Asthma; D002675:Child, Preschool; D000075202:Contraindications; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D007121:Immunocompetence; D007223:Infant; D007252:Influenza Vaccines / Q000008:administration & dosage* / Q000009:adverse effects*; D007251:Influenza, Human / Q000517:prevention & control; D011358:Product Surveillance, Postmarketing; D012135:Respiratory Sounds; D014481:United States; D014611:Vaccination / Q000009:adverse effects / Q000706:statistics & numerical data*; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D007252:Influenza Vaccines; D014613:Vaccines, Attenuated